Close Menu

You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.

Home » Business, Policy & Funding » Business News » Silence Inks Delivery Tech Evaluation Deal with Mireven

Silence Inks Delivery Tech Evaluation Deal with Mireven

Aug 23, 2012
Premium

Silence Therapeutics this week announced that it has struck a deal under which its delivery technologies will be evaluated by Australian microRNA drug developer Mireven for use with its therapeutic candidates.

Silence will formulate a mimic of miR-7 using its three lipid-based delivery technologies: AtuPlex, which is used in the company's phase I siRNA cancer drug Atu-027; DACC, which selectively targets the lung endothelium; and DBTC, which targets liver cells.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The Scan

Genomics to Trace, Prevent

Nature News reports that genomics is being applied to trace and try to prevent additional COVID-19 waves.

Sense of Scope in San Diego

Rady's Children Hospital and San Diego County are teaming up to test pediatric patients and their families for COVID-19 to gauge the spread of the virus locally, according to the San Diego Union-Tribune.

Boost to Wolf Diversity

Wildlife managers aim to boost the genetic diversity of Mexican gray wolves by placing captive-born foster pups into packs with similarly aged wild pups, the Mercury News reports.

Science Papers Present Algorithm to Diagnose Slowly Progressing Diseases, Korean Genome Project

In Science this week: Genetic Probability tool identifies likely diagnoses in 45 percent of inflammatory arthritis cases, and more.

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2020 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.